Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7M1H

Crystal structure of LC/A-JPU-C10-JPU-D12-JPU-B8-JPU-G3-ciA-F12-ciA-D12

7M1H の概要
エントリーDOI10.2210/pdb7m1h/pdb
分子名称Botulinum neurotoxin A light chain, JPU-D12, ciA-F12, ... (9 entities in total)
機能のキーワードvhh, protease domain, toxin, antitoxin
由来する生物種Clostridium botulinum
詳細
タンパク質・核酸の鎖数7
化学式量合計134059.06
構造登録者
Lam, K.,Jin, R. (登録日: 2021-03-13, 公開日: 2021-12-22, 最終更新日: 2024-11-06)
主引用文献Lam, K.H.,Tremblay, J.M.,Perry, K.,Ichtchenko, K.,Shoemaker, C.B.,Jin, R.
Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies.
Plos Pathog., 18:e1010169-e1010169, 2022
Cited by
PubMed Abstract: Botulinum neurotoxins (BoNTs) are among the deadliest of bacterial toxins. BoNT serotype A and B in particular pose the most serious threat to humans because of their high potency and persistence. To date, there is no effective treatment for late post-exposure therapy of botulism patients. Here, we aim to develop single-domain variable heavy-chain (VHH) antibodies targeting the protease domains (also known as the light chain, LC) of BoNT/A and BoNT/B as antidotes for post-intoxication treatments. Using a combination of X-ray crystallography and biochemical assays, we investigated the structures and inhibition mechanisms of a dozen unique VHHs that recognize four and three non-overlapping epitopes on the LC of BoNT/A and BoNT/B, respectively. We show that the VHHs that inhibit the LC activity occupy the extended substrate-recognition exosites or the cleavage pocket of LC/A or LC/B and thus block substrate binding. Notably, we identified several VHHs that recognize highly conserved epitopes across BoNT/A or BoNT/B subtypes, suggesting that these VHHs exhibit broad subtype efficacy. Further, we identify two novel conformations of the full-length LC/A, that could aid future development of inhibitors against BoNT/A. Our studies lay the foundation for structure-based engineering of protein- or peptide-based BoNT inhibitors with enhanced potencies and cross-subtypes properties.
PubMed: 34990480
DOI: 10.1371/journal.ppat.1010169
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.78 Å)
構造検証レポート
Validation report summary of 7m1h
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon